CORNELL UNIVERSITY;SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人:
CHIOSIS GABRIELA,TALDONE TONY,ALPAUGH MARY L.,GOMES-DAGAMA ERICA M.,GUZMAN MONICA L.,ZONG HONGLIANG
申请号：
NZ62063412
公开号：
NZ620634A
申请日:
2012.07.06
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
A method for determining whether a patient with a blood cancer will likely respond to therapy with an HSP90 inhibitor comprises (a) contacting a sample containing blood cancer cells and non-cancerous blood cells from the patient with a cell permeable fluorescently labeled HSP90 inhibitor that binds directly and preferentially to a tumor-specific form of HSP90 present in the cancer cells of the patient； (b) measuring the amount of fluorescently labeled HSP90 inhibitor bound to HSP90 protein in the cancer cells and non-cancerous cells in the sample； and (c) comparing the amount of the fluorescently labeled HSP90 inhibitor bound to the cancer cells with the amount of the fluorescently labeled HSP90 inhibitor bound to the non-cancerous cells. A greater amount of fluorescently labeled HSP90 inhibitor bound to the cancer cells than the non-cancerous cells indicates presence of the tumor specific form of HSP90 in the cancer cells； thereby determining that the blood cancer will likely respond to the HSP90 inhibitor.
